AMRX
Price
$9.55
Change
+$0.01 (+0.10%)
Updated
Sep 4, 04:59 PM (EDT)
Capitalization
3B
64 days until earnings call
PAHC
Price
$39.05
Change
+$0.86 (+2.25%)
Updated
Sep 4, 04:59 PM (EDT)
Capitalization
1.58B
62 days until earnings call
Interact to see
Advertisement

AMRX vs PAHC

Header iconAMRX vs PAHC Comparison
Open Charts AMRX vs PAHCBanner chart's image
Amneal Pharmaceuticals
Price$9.55
Change+$0.01 (+0.10%)
Volume$45.64K
Capitalization3B
Phibro Animal Health
Price$39.05
Change+$0.86 (+2.25%)
Volume$6.16K
Capitalization1.58B
AMRX vs PAHC Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. PAHC commentary
Sep 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Buy and PAHC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2025
Stock price -- (AMRX: $9.54 vs. PAHC: $38.19)
Brand notoriety: AMRX and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 90% vs. PAHC: 156%
Market capitalization -- AMRX: $3B vs. PAHC: $1.58B
AMRX [@Pharmaceuticals: Generic] is valued at $3B. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.58B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.9B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than AMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 5 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 5 bullish, 4 bearish.
  • PAHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AMRX and PAHC are a good buy in the short-term.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +1.92% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +19.01% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.12%. For the same industry, the average monthly price growth was +8.26%, and the average quarterly price growth was +84.01%.

Reported Earning Dates

AMRX is expected to report earnings on Nov 07, 2025.

PAHC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.12% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($3B) has a higher market cap than PAHC($1.58B). AMRX has higher P/E ratio than PAHC: AMRX (955.00) vs PAHC (32.83). PAHC YTD gains are higher at: 84.301 vs. AMRX (20.455). AMRX has higher annual earnings (EBITDA): 584M vs. PAHC (147M). PAHC has less debt than AMRX: PAHC (762M) vs AMRX (2.58B). AMRX has higher revenues than PAHC: AMRX (2.85B) vs PAHC (1.3B).
AMRXPAHCAMRX / PAHC
Capitalization3B1.58B189%
EBITDA584M147M397%
Gain YTD20.45584.30124%
P/E Ratio955.0032.832,909%
Revenue2.85B1.3B220%
Total Cash71.5MN/A-
Total Debt2.58B762M339%
FUNDAMENTALS RATINGS
AMRX vs PAHC: Fundamental Ratings
AMRX
PAHC
OUTLOOK RATING
1..100
2619
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
5239
SMR RATING
1..100
9949
PRICE GROWTH RATING
1..100
4236
P/E GROWTH RATING
1..100
30100
SEASONALITY SCORE
1..100
3146

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (28) in the Pharmaceuticals Major industry is significantly better than the same rating for AMRX (99). This means that PAHC’s stock grew significantly faster than AMRX’s over the last 12 months.

PAHC's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is in the same range as AMRX (52). This means that PAHC’s stock grew similarly to AMRX’s over the last 12 months.

PAHC's SMR Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMRX (99). This means that PAHC’s stock grew somewhat faster than AMRX’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as AMRX (42). This means that PAHC’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's P/E Growth Rating (30) in the Pharmaceuticals Major industry is significantly better than the same rating for PAHC (100). This means that AMRX’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXPAHC
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 14 days ago
71%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PDSIX48.34N/A
N/A
PGIM Quant Solutions Large-Cap Index I
IJSIX14.61N/A
N/A
VY® JPMorgan Small Cap Core Equity I
JDVWX24.95N/A
N/A
JHancock Disciplined Value R6
ACIZX55.46N/A
N/A
Alger Capital Appreciation Instl Z-2
ARZDX6.17N/A
N/A
AMG River Road Dividend All Cap Value Z

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+4.46%
AMRX - PAHC
48%
Loosely correlated
-0.42%
PBH - PAHC
42%
Loosely correlated
+0.62%
ZTS - PAHC
41%
Loosely correlated
-0.29%
ELAN - PAHC
39%
Loosely correlated
-2.80%
COLL - PAHC
36%
Loosely correlated
+1.05%
More